Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Hammond

Showing results (661-670 of 711) with videos related to

Pageof 72
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2022
Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid TumorsJonathan W Goldman, Sarina A Piha-Paul, Brendan Curti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2006
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal functionAlain C Mita, Christopher J Sweeney, Sharyn D Baker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2002
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeksM L Rothenberg, J G Kuhn, L J Schaaf, et al.
The New England Journal of Medicine|March 19, 2015
Brain swelling and death in children with cerebral malariaKarl B Seydel, Samuel D Kampondeni, Clarissa Valim, et al.
Clinical Immunology (Orlando, Fla.)|April 19, 2015
Tuberculosis specific responses following therapy for TB: Impact of HIV co-infectionS Siddiqui, Y Sarro, B Diarra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunctionLarry J Schaaf, Lisa A Hammond, Stuart J Tipping, et al.
Frontiers in Immunology|March 25, 2021
Tertiary Lymphoid Structure-B Cells Narrow Regulatory T Cells Impact in Lung Cancer PatientsClaire Germain, Priyanka Devi-Marulkar, Samantha Knockaert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumorsR L Drengler, J G Kuhn, L J Schaaf, et al.
Cancer Immunology Research|May 7, 2015
Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal AntibodyRoss Stewart, Michelle Morrow, Scott A Hammond, et al.
Npj Complexity|September 4, 2025
One pathogen does not an epidemic make: a review of interacting contagions, diseases, beliefs, and storiesLaurent Hébert-Dufresne, Yong-Yeol Ahn, Antoine Allard, et al.
Pageof 72

Showing results (661-670 of 711) with videos related to

Sort By:
Pageof 72
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2022
Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid TumorsJonathan W Goldman, Sarina A Piha-Paul, Brendan Curti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2006
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal functionAlain C Mita, Christopher J Sweeney, Sharyn D Baker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2002
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeksM L Rothenberg, J G Kuhn, L J Schaaf, et al.
The New England Journal of Medicine|March 19, 2015
Brain swelling and death in children with cerebral malariaKarl B Seydel, Samuel D Kampondeni, Clarissa Valim, et al.
Clinical Immunology (Orlando, Fla.)|April 19, 2015
Tuberculosis specific responses following therapy for TB: Impact of HIV co-infectionS Siddiqui, Y Sarro, B Diarra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunctionLarry J Schaaf, Lisa A Hammond, Stuart J Tipping, et al.
Frontiers in Immunology|March 25, 2021
Tertiary Lymphoid Structure-B Cells Narrow Regulatory T Cells Impact in Lung Cancer PatientsClaire Germain, Priyanka Devi-Marulkar, Samantha Knockaert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumorsR L Drengler, J G Kuhn, L J Schaaf, et al.
Cancer Immunology Research|May 7, 2015
Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal AntibodyRoss Stewart, Michelle Morrow, Scott A Hammond, et al.
Npj Complexity|September 4, 2025
One pathogen does not an epidemic make: a review of interacting contagions, diseases, beliefs, and storiesLaurent Hébert-Dufresne, Yong-Yeol Ahn, Antoine Allard, et al.
Pageof 72